BIF002 / City of Hope - LARVOL DELTA

IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs) (ASH 2023) - "In summary, we provide evidence of the subnanomolar potency and efficacy of BIF002, a novel anti-IL1RAP/CD3 TCE, in eliminating AML blasts, including LSCs. BIF002 is currently undergoing IND-enabling studies."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • CD34 • IL1RAP

IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. (PubMed, J Hematol Oncol) - "The novel anti-IL1RAP/CD3 TCE, BIF002, eradicates LSCs and significantly prolongs survival of AML xenografts, representing a promising, novel treatment for AML."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CD34 • IL1RAP • SDC1

City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting (Businesswire) - "To find a therapeutic workaround for acute myeloid leukemia (AML), City of Hope researchers created a mouse-human chimeric bispecific T cell engager called BiF002 that incorporates a human form of immunoglobulin G....In three different mouse models, BIF002 significantly impeded disease progression and prolonged the lives of mice with human AML, all without causing side effects,..."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology